Neuraxpharm and Panaxia have continued to push forward with their partnership on medical cannabis, exporting sublingual tablets to France as part of a pilot program organized by local regulator ANSM.

Neuraxpharm and Panaxia have become the first companies in the world to market medical cannabis extract, under the joint brand Naxiva-Panaxol, for vaporization in Germany. Under the agreement, the extracts will be manufactured by Panaxia and marketed in Germany by Neuraxpharm. 

CNS specialist Neuraxpharm has announced expanding its strategic collaboration with Panaxia Labs Israel for advanced medical cannabis-based pharmaceutical products to Poland, after Germany and France. The companies expect sale of the cannabis portfolio to commence in the first half of 2022.